MRK Overview
Upcoming Projects (MRK)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (MRK)
-
A second look: Discussing the treatment landscape for cervical cancer
Tickers: MRK, PFE
Executed On: Sep 18, 2024 at 04:00 PM EDT -
Discussing the treatment landscape for cervical cancer
Tickers: MRK, PFE
Executed On: Sep 10, 2024 at 12:00 PM EDT -
Discussing the potential of Vaxcyte's VAX-31 and VAX-24, pneumococcal conjugate vaccine (PCV) candidates designed to prevent invasive pneumococcal disease (IPD)
Tickers: PCVX, MRK, PFE
Executed On: Sep 05, 2024 at 03:30 PM EDT -
Exploring Merck Pharmaceuticals data for vibostolimab coformulated with pembrolizumab (vibo/pembro) for treatment of advanced mismatch repair–deficient (dMMR) endometrial cancer presented ASCO 2024
Ticker: MRK
Executed On: Jul 03, 2024 at 11:00 AM EDT -
A Second Opinion: Understanding the latest updates and clinical development trends in SCLC from ASCO 2024
Tickers: AMGN, ABBV, GSK, MRK
Executed On: Jun 20, 2024 at 02:30 PM EDT -
Discussing Summit's ivonescimab and the results of the HARMONi-2 trial in Non-Small Cell Lung Cancer (NCSLC)
Tickers: SMMT, MRK
Executed On: Jun 13, 2024 at 04:00 PM EDT -
Understanding the latest updates and clinical development trends in SCLC from ASCO 2024
Tickers: AMGN, ABBV, GSK, MRK
Executed On: Jun 12, 2024 at 11:00 AM EDT -
Digging into the phase 2 KRYSTAL-7 clinical trial results of adagrasib with pembrolizumab as a treatment for non-small cell lung cancer as presented at ESMO 2023
Tickers: MRTX, MRK
Executed On: Nov 29, 2023 at 01:30 PM EST -
Quarterly Survey: LR-MDS Pts RBC Transfusions and Reblozyl (luspatercept) - October 2023
Tickers: BMY, MRK, GERN, ELRN
Executed On: Nov 02, 2023 at 05:25 PM EDT -
A broad discussion looking at the competitive landscape of the Life Science antibody and reagent market
Tickers: TMO, MRK, A, BIO
Executed On: Sep 20, 2023 at 10:00 AM EDT -
A Second Look: Discussing the potential of the Optilume Benign Prostatic Hyperplasia Catheter and Balloon system from Urotronic and how it compares to medications from Merck, GSK, and Astellas.
Tickers: UROTRONIC, ALPMY, MRK, GSK
Executed On: Sep 01, 2023 at 08:00 AM EDT -
Discussing the potential of the Optilume Benign Prostatic Hyperplasia Catheter and Balloon system from Urotronic and how it compares to medications from Merck, GSK, and Astellas.
Tickers: UROTRONIC, ALPMY, MRK, GSK
Executed On: Aug 25, 2023 at 09:00 AM EDT -
Diving into the label expansion for Merck's Prevymis (letermovir) for prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients
Ticker: MRK
Executed On: Aug 01, 2023 at 04:00 PM EDT -
Quarterly Survey: LR-MDS Pts RBC Transfusions and Reblozyl (luspatercept) - July 2023
Tickers: BMY, MRK, GERN, ELRN
Executed On: Aug 01, 2023 at 03:55 PM EDT -
Quarterly Survey: BMY's Reblozyl (luspatercept) and LR-MDS requiring Red Blood Cell Transfusions May 2023
Tickers: BMY, XLRN, MRK, GERN
Executed On: May 10, 2023 at 12:29 PM EDT -
Discussing therapeutics in development for melanoma including Moderna/Merck's mRNA-4157 cancer vaccine and Iovance Biotherapeutics' TIL therapy, lifileucel.
Tickers: MRNA, IOVA, MRK
Executed On: May 09, 2023 at 10:30 AM EDT -
A Second View: Delving into the Phase 3 STELLAR trial data released at ACC 2023 on Merck's sotatercept for treating PAH
Tickers: MRK, UTHR
Executed On: Apr 11, 2023 at 06:00 PM EDT -
Delving into the Phase 3 STELLAR trial data released at ACC 2023 on Merck's sotatercept for treating PAH
Tickers: MRK, UTHR
Executed On: Apr 03, 2023 at 05:30 PM EDT -
Digging in to the Phase 2b data presented at the AAC Conference for Merck's oral PCSK9 inhibitor, MK-0616, in patients with hypercholesterolemia
Ticker: MRK
Executed On: Mar 16, 2023 at 09:00 AM EDT -
Examining the clinical landscape of renal disease and the potential of anticoagulant therapies in this space for the prevention of cardiovascular events, including Merck's MK-2060.
Ticker: MRK
Executed On: Sep 09, 2022 at 01:00 PM EDT -
A look at Quviviq for treatment in adults with insomnia and how it compares to competitors in this space
Tickers: IDRSF, MRK
Executed On: Aug 31, 2022 at 01:30 PM EDT -
Discussing Bellus BLU-5937 against Merck's gefapixant in Chronic cough, following recent Phase 2b results and FDA meeting
Tickers: BLU, MRK
Executed On: Jul 14, 2022 at 10:00 AM EDT -
A look at Verquvo following its FDA approval to reduce the risk of cardiovascular death and heart failure hospitalization
Ticker: MRK
Executed On: May 04, 2022 at 02:30 PM EDT -
A Second View: Discussing Welireg (Belzutifan) as a treatment in patients with von Hippel-Lindau (VHL) disease with associated renal cell carcinoma
Ticker: MRK
Executed On: Mar 23, 2022 at 04:30 PM EDT -
Discussing Welireg (Belzutifan) as a treatment in patients with von Hippel-Lindau (VHL) disease with associated renal cell carcinoma
Ticker: MRK
Executed On: Mar 15, 2022 at 10:00 AM EDT
Expired Projects (MRK)
-
Digging into Merck's Keytruda as a first-line monotherapy in locally advanced or metastatic NSCLC with TPS of ≥1
Ticker: MRK
Execute By: May 09, 2019 -
Evaluating the Market Potential of Hua Medicine's HMS5552 in Type II Diabetes Ahead of Mid-Year Phase II Readout. Does the drug have potential to derail the success of major players in the space?
Tickers: HUA MEDICINE, ABT, AZN, NVS, NVO, MRK, SNY, GSK, Lupin Pharmaceuticals, RHHBY
Execute By: May 11, 2016 -
To see if we can get the specific DOJ requests to Pharma companies on drug pricing. These investigations have been confirmed in 10q filings.
Tickers: MRK, VRX, LLY
Execute By: Mar 04, 2016
Upcoming & Overdue Catalysts (MRK)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (MRK)
-
Merck’s (MRK) KEYTRUDA (pembrolizumab) Phase 2 KEYNOTE-158 Study in Patients with Advanced Small Cell Lung Cancer (SCLC) Data Released
Ticker: MRK
Occurred on: Jun 04, 2018 -
First-Line Lung Cancer Data and Other New Research from Merck’s Broad Oncology Program to be Presented at AACR Annual Meeting
Ticker: MRK
Occurred on: Apr 16, 2018 -
Top-line data from the Open label Phase 2 trial comparing ridinilazole to fidaxomicin is expected to be reported in Q2 2017
Tickers: SMMT, MRK
Occurred on: Oct 09, 2017 -
FDA Decision Expected By April 5th for Merck's (MRK) Glargine (MK-1293) in Type 1 and Type 2 Diabetes
Tickers: MRK, SNY, LLY, NVO
Occurred on: Jul 20, 2017 -
MRK's CETP CV outcomes for hypercholesterolemia expected in Q1 2017
Tickers: MRK, AMGN, ESPR
Occurred on: Jun 27, 2017 -
Aralez Pharmaceuticals (ARLZ) commences full-scale commercial launch of former Merck (MRK) product Zontivity
Tickers: ARLZ, MRK
Occurred on: Jun 07, 2017 -
PUDFA date for KEYTRUDA in treating Microsatellite Instability-High Cancer set for June 9, 2017
Ticker: MRK
Occurred on: May 25, 2017 -
FDAA approves Merck & co. (MRK) product KEYTRUDA® (pembrolizumab) for the treatment of non-squamous non-small cell lung cance (NSCLC)
Ticker: MRK
Occurred on: May 10, 2017 -
PUDFA date for KEYTRUDA in treating Relapsed or Refractory Classical Hodgkin Lymphoma set on March 15 2017
Ticker: MRK
Occurred on: Mar 14, 2017 -
OncoSec Medical (ONCS) Phase 2 Results Evaluating ImmunoPulse IL-12 and Merck's (MRK) Keytruda in Metastatic Melanoma
Tickers: ONCS, MRK
Occurred on: Feb 23, 2017 -
Merck's (MRK) Marketing Authorization Application (MAA) for Avelumab in Rare Skin Cancer Validated by European Medicines Agency (EMA)
Ticker: MRK
Occurred on: Oct 31, 2016 -
Merck (MRK) Announces Phase 3 KEYNOTE-045 Results Evaluating Keytruda in Advanced Urothelial Cancer
Ticker: MRK
Occurred on: Oct 21, 2016 -
FDA Announces Black Box Requirement for Risk of HBV Reactivation for at Least 9 Brand Name Drugs in Hepatitis C Treatment
Tickers: GILD, ABBV, MRK
Occurred on: Oct 05, 2016 -
BioLineRX (BLRX) Initiates Phase 2a Trial Evaluating BL-8040 + Merck's (MRK) KEYTRUDA in Treatment of Pancreatic Cancer
Tickers: BLRX, MRK
Occurred on: Sep 20, 2016 -
Merck (MRK) and Pfizer (PFE) Announce Phase 3 Results for Type 2 Diabetes Candidate Ertugliflozin
Tickers: MRK, PFE
Occurred on: Sep 15, 2016 -
Teva (TEVA) Launches Generic Version of Merck's CUBICIN for Complicated Skin and Bloodstream Infections in U.S
Tickers: MRK, TEVA
Occurred on: Sep 15, 2016 -
Merck's osteoporosis candidate odanacatib development terminated
Ticker: MRK
Occurred on: Sep 02, 2016 -
NDA to be Filed for Odanacatib for Treatment of Osteoporosis in 2016 Pending Long Safety Review
Ticker: MRK
Occurred on: Sep 02, 2016 -
Phase 1b study assessing AFM13/KEYTRUDA combo in lymphoma to be initiated in the first half of 2016
Tickers: AFMD, MRK
Occurred on: Aug 10, 2016 -
Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920)
Ticker: MRK
Occurred on: Jul 25, 2016 -
Merck Animal Health Receives FDA Approval of BRAVECTO (fluralaner topical solution) for Cats and Dogs
Ticker: MRK
Occurred on: Jul 21, 2016 -
Incyte set to initiate Phase 3 study of epacadostat plus pembrolizumab in first-line advanced melanoma
Tickers: INCY, MRK
Occurred on: Jun 22, 2016 -
Merck’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus
Ticker: MRK
Occurred on: Jun 13, 2016 -
Merck Receives Positive CHMP Opinion for ZEPATIER (elbasvir and grazoprevir) in the European Union
Ticker: MRK
Occurred on: May 27, 2016 -
Merck (MRK) Expects to File NDA for DPP-4 Inhibitor Omarigliptin in Treatment of Type 2 Diabetes by End of 2016 - Cancelled
Ticker: MRK
Occurred on: Apr 08, 2016 -
Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts
Tickers: ADXS, MRK
Occurred on: Apr 05, 2016 -
FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
Ticker: MRK
Occurred on: Mar 07, 2016 -
FDA’s Arthritis Advisory Committee Recommends Approval of Celltrion’s CT-P13, a Proposed Biosimilar Infliximab, for All Eligible Indications
Tickers: CELLTRION, PFE, MRK, JNJ
Occurred on: Feb 10, 2016 -
FDA reviewers support Celltrion's biosimilar Remicade, ahead of the Ad Comm meeting on February 9
Tickers: CELLTRION, PFE, JNJ, MRK
Occurred on: Feb 05, 2016 -
FDA's Advisory Committee Votes in Favor of Approval of Merck's (MRK) Muscle Relaxant Reversal Agent BRIDION
Ticker: MRK
Occurred on: Nov 06, 2015 -
Merck (MRK) Receives Inquiries Over Certain Aspects of Drug Pricing
Tickers: MRK, VRX, LLY, Turing
Occurred on: Oct 19, 2015 -
Lilly (LLY) Receives Inquiries Over Certain Aspects of Drug Pricing (Date is an estimate for "September")
Tickers: LLY, VRX, MRK
Occurred on: Sep 15, 2015
Strategic Initiatives (MRK)
-
Merk (MRK) is set to acquire ArQule (ARQL) at $20 per share in cash for an approximate total equity value of $2.7 billion
Tickers: ARQL, MRK
Announcement Date: Dec 09, 2019 -
Merck Discontinues MK-3682B and MK-3682C Development Programs
Tickers: MRK, GILD
Announcement Date: Sep 29, 2017 -
Lilly (LLY) and Merck (MRK) Expand Existing Oncology Collaboration, Agree to Evaluating Lartruvo + Keytruda in Advanced/Metastatic Soft Tissue Sarcoma
Tickers: LLY, MRK
Announcement Date: Jan 11, 2017 -
Vertex (VRTX) and Merck KgaA (MKGAY) Announce Collaboration and License Agreement Covering Four Oncology R&D Programs
Tickers: MRK, VRTX, MKGAY
Announcement Date: Jan 11, 2017 -
Incyte (INCY) and Merck (MRK) Expand Collaboration Agreement Investigating Epacadostat + Keytruda in Solid Tumors and Blood Cancers
Tickers: MRK, INCY
Announcement Date: Jan 09, 2017 -
HTG Molecular (HTGM) Agrees to Develop Companion Diagnostic Tests for Merck KGaA's (MKGAY) Cancer Candidates
Tickers: HTGM, MRK, MKGAY
Announcement Date: Oct 11, 2016 -
Agenus Announces Lead Product Candidate Selection in its Collaboration with Merck
Tickers: AGEN, MRK
Announcement Date: Jun 09, 2016 -
Merck and Sanofi Pasteur end joint vaccine operations in Europe
Tickers: SNY, MRK
Announcement Date: Mar 08, 2016 -
Merck KGaA, Darmstadt, Germany, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
Tickers: MRK, PFE, VSTM
Announcement Date: Mar 03, 2016